Neuroprotective role of erythropoietin in neonates

References

• Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R, Adler A, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet 2012;379:2162–2172.
   PubMed Web of Science ®Google Scholar
• Marlow N, Wolke D, Bracewell MA, Samara M; EPICure Study Group. Neurologic and developmental disability at six years of age after extremely preterm birth. N Engl J Med 2005;352:9–19.
   PubMed Web of Science ®Google Scholar
• Russell RB, Green NS, Steiner CA, Meikle S, Howse JL, Poschman K, Dias T, et al. Cost of hospitalization for preterm and low birth weight infants in the United States. Pediatrics 2007;120:e1–e9.
   PubMed Web of Science ®Google Scholar
• Volpe JJ. The encephalopathy of prematurity–brain injury and impaired brain development inextricably intertwined. Semin Pediatr Neurol 2009;16:167–178.
   PubMed Web of Science ®Google Scholar
• Tagin MA, Woolcott CG, Vincer MJ, Whyte RK, Stinson DA. Hypothermia for neonatal hypoxic ischemic encephalopathy: an updated systematic review and meta-analysis. Arch Pediatr Adolesc Med 2012 (Epub ahead of print).
   PubMedGoogle Scholar
• van der Kooij MA, Groenendaal F, Kavelaars A, Heijnen CJ, van Bel F. Neuroprotective properties and mechanisms of erythropoietin in in vitro and in vivo experimental models for hypoxia/ischemia. Brain Res Rev 2008;59:22–33.
   PubMedGoogle Scholar
• Favrais G, van de Looij Y, Fleiss B, Ramanantsoa N, Bonnin P, Stoltenburg-Didinger G, Lacaud A, et al. Systemic inflammation disrupts the developmental program of white matter. Ann Neurol 2011;70:550–565.
   PubMed Web of Science ®Google Scholar
• Sun Y, Calvert JW, Zhang JH. Neonatal hypoxia/ischemia is associated with decreased inflammatory mediators after erythropoietin administration. Stroke 2005;36:1672–1678.
   PubMed Web of Science ®Google Scholar
• Juul SE, Beyer RP, Bammler TK, McPherson RJ, Wilkerson J, Farin FM. Microarray analysis of high-dose recombinant erythropoietin treatment of unilateral brain injury in neonatal mouse hippocampus. Pediatr Res 2009;65:485–492.
   PubMed Web of Science ®Google Scholar
• Volpe JJ. Brain injury in premature infants: a complex amalgam of destructive and developmental disturbances. Lancet Neurol 2009;8:110–124.
   PubMed Web of Science ®Google Scholar
• Iwai M, Stetler RA, Xing J, Hu X, Gao Y, Zhang W, Chen J, Cao G. Enhanced oligodendrogenesis and recovery of neurological function by erythropoietin after neonatal hypoxic/ischemic brain injury. Stroke 2010;41:1032–1037.
   PubMed Web of Science ®Google Scholar
• Xiong T, Qu Y, Mu D, Ferriero D. Erythropoietin for neonatal brain injury: opportunity and challenge. Int J Dev Neurosci 2011;28:583–591.
   Google Scholar
• Iwai M, Cao G, Yin W, Stetler RA, Liu J, Chen J. Erythropoietin promotes neuronal replacement through revascularization and neurogenesis after neonatal hypoxia/ischemia in rats. Stroke 2007;38:2795–2803.
   PubMed Web of Science ®Google Scholar
• Juul S, Felderhoff-Mueser U. Epo and other hematopoietic factors. Semin Fetal Neonatal Med 2007;12:250–258.
   PubMed Web of Science ®Google Scholar
• Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2006;CD004863.
   PubMedGoogle Scholar
• Doege C, Pritsch M, Frühwald MC, Bauer J. An association between infantile haemangiomas and erythropoietin treatment in preterm infants. Arch Dis Child Fetal Neonatal Ed 2012;97:F45–F49.
   PubMed Web of Science ®Google Scholar
• Juul SE, McPherson RJ, Bauer LA, Ledbetter KJ, Gleason CA, Mayock DE. A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety. Pediatrics 2008;122:383–391.
   PubMed Web of Science ®Google Scholar
• Kellert BA, McPherson RJ, Juul SE. A comparison of high-dose recombinant erythropoietin treatment regimens in brain-injured neonatal rats. Pediatr Res 2007;61:451–455.
   PubMed Web of Science ®Google Scholar
• Wu YW, Bauer LA, Ballard RA, Ferriero DM, Glidden DV, Mayock DE, Chang Durand DJ, et al. High-dose erythropoietin for neuroprotection in neonatal encephalopathy: a Phase I Safety and Pharmacokinetic Study. Pediatrics. 2012 (In Press).
   Google Scholar
• Fauchère JC, Dame C, Vonthein R, Koller B, Arri S, Wolf M, Bucher HU. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics 2008;122:375–382.
   PubMed Web of Science ®Google Scholar
• Elmahdy H, El-Mashad AR, El-Bahrawy H, El-Gohary T, El-Barbary A, Aly H. Human recombinant erythropoietin in asphyxia neonatorum: pilot trial. Pediatrics 2010;125:e1135–e1142.
   PubMed Web of Science ®Google Scholar
• Statler PA, McPherson RJ, Bauer LA, Kellert BA, Juul SE. Pharmacokinetics of high-dose recombinant erythropoietin in plasma and brain of neonatal rats. Pediatr Res 2007;61(6):671–675.
   PubMedGoogle Scholar
• Juul SE, McPherson RJ, Bauer LA, Ledbetter KJ, Gleason CA, Mayock DE. A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety. Pediatrics 2008;122(2):383–391.
   PubMedGoogle Scholar